Biodesix to Present at TD Cowen 45th Annual Health Care Conference
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has announced its participation in the TD Cowen 45th Annual Health Care Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on March 5, 2025.
The presentation is scheduled for 1:50 PM ET in Boston, MA. Investors and interested parties can access the live webcast and replay through the 'News & Events' section of the Investors page on biodesix.com.
Biodesix (Nasdaq: BDSX), un'azienda di soluzioni diagnostiche, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Il CEO Scott Hutton e il CFO Robin Cowie parteciperanno a una chiacchierata informale e condurranno incontri individuali con gli investitori il 5 marzo 2025.
La presentazione è programmata per le 13:50 ET a Boston, MA. Gli investitori e le parti interessate possono accedere alla diretta e alla registrazione tramite la sezione 'Notizie ed Eventi' della pagina Investitori su biodesix.com.
Biodesix (Nasdaq: BDSX), una empresa de soluciones diagnósticas, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. El CEO Scott Hutton y el CFO Robin Cowie participarán en una charla informal y realizarán reuniones individuales con inversores el 5 de marzo de 2025.
La presentación está programada para la 1:50 PM ET en Boston, MA. Los inversores y partes interesadas pueden acceder a la transmisión en vivo y la repetición a través de la sección 'Noticias y Eventos' de la página de Inversores en biodesix.com.
Biodesix (Nasdaq: BDSX), 진단 솔루션 회사가 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. CEO Scott Hutton과 CFO Robin Cowie는 2025년 3월 5일에 화상 대화에 참여하고 투자자와의 일대일 회의를 진행할 예정입니다.
발표는 보스턴, MA에서 동부 표준시 기준으로 오후 1시 50분에 예정되어 있습니다. 투자자 및 관심 있는 분들은 biodesix.com의 투자자 페이지 '뉴스 및 이벤트' 섹션을 통해 생중계 및 재생을 이용할 수 있습니다.
Biodesix (Nasdaq: BDSX), une entreprise de solutions diagnostiques, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. Le PDG Scott Hutton et le CFO Robin Cowie participeront à une discussion informelle et organiseront des réunions individuelles avec des investisseurs le 5 mars 2025.
La présentation est prévue pour 13h50 ET à Boston, MA. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à la rediffusion via la section 'Actualités et Événements' de la page des Investisseurs sur biodesix.com.
Biodesix (Nasdaq: BDSX), ein Unternehmen für diagnostische Lösungen, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. CEO Scott Hutton und CFO Robin Cowie werden am 5. März 2025 an einem informellen Gespräch teilnehmen und individuelle Investorenmeetings durchführen.
Die Präsentation ist für 13:50 Uhr ET in Boston, MA, geplant. Investoren und Interessierte können über den Bereich 'Nachrichten & Veranstaltungen' auf der Investorenseite von biodesix.com auf den Live-Stream und die Aufzeichnung zugreifen.
- None.
- None.
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025.
TD Cowen 45th Annual Health Care Conference
Fireside Chat Date: Wednesday, March 5, 2025
Fireside Chat Time: 1:50 PM ET
Location: Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for pulmonology patients. The Nodify Lung® Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The IQLung™ test portfolio for lung cancer patients supports treatment decisions across all stages of lung cancer and expedites personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
1-339-970-284
FAQ
When is Biodesix (BDSX) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Biodesix's (BDSX) TD Cowen conference presentation?
Who will represent Biodesix (BDSX) at the TD Cowen Healthcare Conference?
What type of investor engagement will Biodesix (BDSX) offer at the TD Cowen conference?
